The estimated Net Worth of Jeanette M Bjorkquist is at least $58.3 Tysiąc dollars as of 23 May 2024. Jeanette Bjorkquist owns over 24 units of Assembly Biosciences Inc stock worth over $54,608 and over the last 2 years Jeanette sold ASMB stock worth over $3,671.
Jeanette has made over 5 trades of the Assembly Biosciences Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Jeanette sold 24 units of ASMB stock worth $358 on 23 May 2024.
The largest trade Jeanette's ever made was selling 844 units of Assembly Biosciences Inc stock on 24 July 2023 worth over $903. On average, Jeanette trades about 406 units every 92 days since 2023. As of 23 May 2024 Jeanette still owns at least 3,142 units of Assembly Biosciences Inc stock.
You can see the complete history of Jeanette Bjorkquist stock trades at the bottom of the page.
Jeanette's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak oraz Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Assembly Biosciences Inc executives and other stock owners filed with the SEC include: